On August 26, 2019 (the "Effective Date"), Alpine Immune Sciences, Inc. (the "Company") and its wholly-owned subsidiary, AIS Operating Co., Inc. ("AIS" and together with the Company, the "Borrowers"), reported that it has entered into an Amended and Restated Loan and Security Agreement (the "Loan Agreement") with Silicon Valley Bank (the "Bank"), pursuant to which the Bank agreed to extend term loans to the Company with an aggregate principal amount of up to $15.0 million (the "Term Loans") (Filing, 8-K, Alpine Immune Sciences, AUG 26, 2019, View Source [SID1234551115]). The Company intends to use the proceeds to replace and refinance AIS’ existing loan facility pursuant to the Loan and Security Agreement by and between AIS and the Bank dated as of December 16, 2016 (the "Original Agreement"), as well as for potential working capital and other general corporate purposes, including the advancement of the Company’s development programs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Borrowings under the Loan Agreement will consist of up to three separate tranches. The initial tranche of $5.0 million was funded on August 26, 2019, $3.0 million of which will be used to repay amounts owing under the Original Agreement. The second tranche of up to $5.0 million is available in multiple advances at the Borrowers’ option at any time through April 30, 2020. The third and final tranche of up to $5.0 million is available in multiple advances at the Borrowers’ option at any time from the date on which Bank receives and approves evidence that the Borrowers have initiated a Phase 2a trial of ALPN-101 in psoriatic arthritis through July 31, 2020. Each term loan advance, other than the final term loan advance, must be in an amount of not less than $0.5 million and, after repayment, no term loan advance may be re-borrowed.
The Term Loans shall accrue interest at a floating per annum rate of 0.25% above the prime rate, subject to a floor of 5.75%, which interest is payable monthly commencing in September 2019. Upon the occurrence and during the continuance of an event of default, a default interest rate will apply that is 4.0% above the otherwise applicable interest rate. The Term Loans are interest only until September 30, 2020, after which the Term Loans will be payable in 34 equal monthly installments of principal plus interest, with the final installment due and payable on July 1, 2023. If Borrowers receive aggregate net new capital of at least $40 million on or prior to June 30, 2020, the Term Loans will be interest-only until June 30, 2021, after which the Term Loans will be payable in 25 equal monthly installments of principal plus interest, with the final installment due and payable on July 1, 2023.
The Borrowers may prepay all, but not less than all, of the Term Loans subject to a prepayment fee equal to $75,000, which represents the deferred portion of the final payment due under the Original Agreement, plus the outstanding principal balance under the Term Loans at the time of such prepayment multiplied by (i) 2.0%, if the prepayment occurs on or prior to the first anniversary of the Effective Date, (ii) 1.0%, if the prepayment occurs after the first anniversary of the Effective Date, but on or prior to the second anniversary of the Effective Date or (iii) 0%, if the prepayment occurs after the second anniversary of the Effective Date, but prior to the maturity date for the Term Loan. A fee in the amount of 5.5% of the Term Loans funded is payable to the Bank on the date on which the Term Loans are prepaid, paid or become due and payable in full.
The Loan Agreement contains customary representations and warranties, events of default (including an event of default upon a material adverse change of the Borrowers) and affirmative and negative covenants, including, among others, covenants that limit or restrict the Borrowers’ ability to, among other things, incur additional indebtedness, grant liens, merge or consolidate, make acquisitions, pay dividends or other distributions or repurchase equity, make investments, dispose of assets, engage in any new line of business, and enter into certain transactions with affiliates, in each case subject to certain exceptions. As security for its obligations under the Loan Agreement, the Borrowers granted the Bank a first priority security interest on substantially all of Borrowers’ assets, except intellectual property, and subject to certain other exceptions.
The foregoing description of the Loan Agreement is not complete and is qualified in its entirety by reference to the full text of the Loan Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.